scholarly journals Prevalence of beta 2-glycoprotein I antibody in systemic lupus erythematosus patients with beta 2-glycoprotein I dependent antiphospholipid antibodies.

1995 ◽  
Vol 54 (1) ◽  
pp. 73-75 ◽  
Author(s):  
J Matsuda ◽  
N Saitoh ◽  
M Gotoh ◽  
K Gohchi ◽  
M Tsukamoto
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Systemic Lupus ◽  
Glycoprotein I ◽  
Beta 2

scholarly journals Screening Tests of Reproductive Immunology in Systemic Lupus Erythematosus

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Zdenka Ulcova-Gallova ◽  
Alice Mockova ◽  
Miroslava Cedikova
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Phosphatidyl Ethanolamine ◽  
Phosphatidyl Inositol ◽  
Phosphatidyl Serine ◽  
Sperm Cells ◽  
Systemic Lupus ◽  
Ethanolamine Phosphatidyl ◽  
Glycoprotein I ◽  
Beta 2

Female patients in reproductive age with systemic lupus erythematosus and fertility complications together are observed by rheumatologists, gynecologists, and reproductive immunologists. The paper notes the presence of autoantibodies to zona pellucida, to phospholipids (phosphatidyl serine, phosphatidyl ethanolamine, phosphatidyl inositol, phosphatidyl glycerol, phosphatidic acid, annexin V, beta-2 glycoprotein I, and cardiolipin) and of isoantibodies to sperm cells. Isoantibodies to sperm cells are not significantly predominant, but autoimmunity is well expressed in IgG positivity against phosphatidyl inositol, phosphatidyl ethanolamine, phosphatidyl serine, cardiolipin, and beta-2 glycoprotein I, as well as antizona pellucida antibodies in IgG isotype. According to the levels of autoantibodies we have to choose preventive treatment to protect mother and her foetus.

Anti-beta-2 glycoprotein I antibodies in patients with Systemic Lupus Erythematosus and Systemic Sclerosis — Clinical significance

1997 ◽  
Vol 56 ◽  
pp. 475-476
Author(s):  
M.E.A. Evangelopoulos ◽  
D.A. Sotos ◽  
A. Levedakos ◽  
M.E. Mavrikakis ◽  
C.D. Evangelopoulos
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Systemic Sclerosis ◽  
Clinical Significance ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Glycoprotein I ◽  
Beta 2

scholarly journals Systemic Lupus Erythematosus and Antiphospholipid Syndrome

2014 ◽  
Vol 2 (3) ◽  
pp. 544-549
Author(s):  
Aleksandra Plavsic ◽  
Rada Miskovic ◽  
Sanvila Raskovic ◽  
Mirjana Bogic ◽  
Branka Bonaci Nikolic
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Antiphospholipid Syndrome ◽  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Autoimmune Disorder ◽  
Systemic Lupus ◽  
Vascular Thrombosis ◽  
Glycoprotein I ◽  
Independent Entity ◽  
Acquired Thrombophilia

Antiphospholipid syndrome is an autoimmune disorder defined as association of vascular thrombosis and/or pregnancy complications with presence of antiphospholipid antibodies (lupus anticoagulant, anticardiolipin and anti-β2 glycoprotein I). It is the most common cause of acquired thrombophilia, and can occur as an independent entity or in relation with other diseases, especially systemic lupus erythematosus. Presence of antiphospholipid syndrome in systemic lupus erythematosus is additional vaso occlusive factor in already present inflammation, bringing further risk for thrombotic events. Clinical and serological manifestations of antiphospholipid syndrome and systemic lupus erythematosus are very similar, so possible connection for these two autoimmune disorders is assumed.

scholarly journals CLINICAL AND IMMUNOLOGICAL CORRELATIONS IN PATIENTS WITH SYSTEMICLUPUS ERYTHEMATOSUS WITH ANTIPHOSPHOLIPID ANTIBODY SYNDROME

2017 ◽  
Vol 9 (3) ◽  
pp. 7-11 ◽  
Author(s):  
E A Belolipetskaia ◽  
I B Beliaeva ◽  
V I Mazurov ◽  
E A Trofimov ◽  
S V Lapin
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antiphospholipid Antibodies ◽  
Annexin V ◽  
Anticardiolipin Antibodies ◽  
Antiphospholipid Antibody ◽  
Antiphospholipid Antibody Syndrome ◽  
Systemic Lupus ◽  
Glycoprotein I ◽  
Threefold Increase

Antiphospholipid antibodies (aPL): lupus anticoagulant (LA), anticardiolipin antibodies (aCL) and anti-β2-glycoprotein I antibodies (anti-β2GPI) are found in 12 to 44% of systemic lupus erythematosus (SLE) patients. On average, antiphospholipid antibody syndrome (APS) develops in50% of aPL-positive patients with SLE. The seronegative APS is characterized by the absence of the diagnostic levels of "classical" aPL and by the presence of non-criteria aPL: antibodies against pro- thrombin (aPT), antibodies against annexin V, antibodies against phosphatidylethanoamine (aPE), antibodies to phosphatidylserine/prothrombin complex (aPS-PT) and antibodies against negatively charged phospholipids. The presence of four antibodies (LA + aCT + anti-β2GPI + aPT) is associated with a threefold increase in the risk of thrombosis. The presence of aCL and anti-β2GPI in SLE patients with APS and recurrent thromboses is associated with the HLA dRB1 * 0402.

Sign in / Sign up

Export Citation Format

Share Document